Stock News

Three brands will be dropped as global teams take over operations, with full annualized savings forecast for fiscal 2028.

The designation offers a generally applicable 27-month permitting limit, with exclusions, and support identifying financing sources.

Gilead gets exclusive development rights to three discovery programmes, with preclinical and later milestone payments contingent on progress.

SYD1 is fully contracted, but the customer and rent remain undisclosed and the first expansion income is expected in late fiscal 2027.

Three holes extend Main Zone mineralization southward, while the release and assay table give conflicting grades and interval lengths.

ASIC also ended a governance inquiry, while its share-trading investigation into a separate non-employee continues.

The multiyear partnership adds deployment and operations support as Axe works to bring more than US$3.45B of customer projects into production.

China’s indication includes patients aged 16 and older, while Japan’s covers adults; U.S. availability is expected in November after DEA scheduling.

The financing adds 4.99 million shares for East Sudbury work, while final closing remains subject to TSX Venture Exchange acceptance.

The approval adds adults with high-grade, BCG-unresponsive disease ahead of the Jan. 6, 2027 review target.

Cash is payable at closing, subject to antitrust conditions; two announced voucher agreements total US$413 million.

Consolidated copper output was flat at 205,000 tonnes in the third quarter, while the Mongolian operation ran at an annualised 450,000 tonnes.

The 13-person study had no control group and a safety primary endpoint, with a separate CVID readout expected in November.

The Nigerian mine poured 15,515 ounces in the third quarter, while Thor maintained its C$0.0125 quarterly dividend.

The court awarded appeal costs; the A$7.40-a-share deal was terminated in December 2025, and Mayne is pursuing damages.

The sub-level cave is expected to sustain pellet supply through 2035, funded from existing cash reserves and open-pit cash flows.

The miner will keep pursuing an alternative waste-storage design while it anticipates a ministerial redetermination.

The Oct. 7 letter addresses quality-system responses, while Olympus says it brings no new production or distribution restrictions.

PAH sales continue, PH-ILD promotion ends and cash payments run into April 2027; Liquidia expects to fund them without new financing.

Five million proposed shares carry a US$100 stated amount, while the preliminary prospectus leaves the sale price and fees blank.

The adjusted earnings midpoint rises six cents to US$11.10 a share as drug sales grow faster than medical technology revenue.

The Nevada silver explorer staked 382 claims after a May survey outlined silver anomalies and possible copper-silver-gold porphyries.

The estimated true width is 95.3 metres, and the new assays mark the planned data cut-off for an estimate expected in the December quarter.

Kinterra would lift its interest to 22.99 per cent, with both share tranches conditional on approval at the Nov. 4 annual meeting.

The 145-patient MAXPIRe study missed its lung-function endpoint; safety was comparable to placebo and graft-versus-host disease trials continue.

A103 lifts secured AI cloud capacity to 333.5 MW, but has no customer offtake and is expected to be energized in early 2028.

Definitive agreements would consolidate mineral and surface rights, while the issuer has yet to establish a resource for the Peruvian tailings.

The strongest interval sits within the existing resource envelope, while separate drilling supports a 170-metre extension of the Central exploration target.

The treatment improved itch scores by 0.98 points more than placebo, with a supplemental U.S. drug application planned for the first half of 2027.

The uncontrolled SYNCHRONICITY study reported a 3.6-letter vision gain at six months, with improvements maintained through two years.

The Sept. 30 balance is up 7.4 per cent from a year earlier; the client deposits are held at Safe Harbor's partner financial institutions.

The 60 mg dose met ALOFT-IPF's lung-function endpoint, but the topline release gives no effect size or filing date.

The utilities award runs for five years, while a 12-month renewal preserves about £1.2M in annual revenue from an unnamed public-sector customer.

The supplier reports A$373M in payments against A$1.1B of work orders, with delivery expected to finish by the end of 2027.

A retail offer targets another A$5 million, with proceeds for drilling, an accommodation village and work ahead of a mid-2027 investment decision.

Net proceeds are about £8.3M, with £4M allocated to bitcoin and the first weekly dividend payable by Nov. 9.

ICP-B161 is the company's fifth candidate to enter clinical development in 2026; the release gives no enrollment timetable.

The linked customer page carries Oct. 9 closing notices for 13 Florida stores and does not give individual reopening dates.

The FDA has accepted the ADH1 application for priority review, with a May 8, 2027 target decision date.

NexGen describes delivery as several months ahead of planned installation; the post does not give dates for dispatch or installation.